2012
A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa
Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, Aboobaker J, Coovadia HM. A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2012, 60: 150-157. PMID: 22395672, PMCID: PMC3360837, DOI: 10.1097/qai.0b013e318251aedd.Peer-Reviewed Original ResearchConceptsHIV-KSKing Edward VIII HospitalSymptomatic visceral diseaseActive antiretroviral therapyOpen-label trialTreatment-naive patientsTertiary referral centerAdministration of chemotherapyHAART armUrgent chemotherapyAntiretroviral therapyReferral centerVisceral diseaseTreat analysisKaposi's sarcomaHAARTChemotherapySaharan AfricaOptimal approachHIVLamivudinePatientsSarcomaStavudineNevirapine
2002
A Phase II Randomized Study of the Virologic and Immunologic Effect of Zidovudine + Stavudine versus Stavudine Alone and Zidovudine + Lamivudine in Patients with >300 CD4 Cells Who Were Antiretroviral Naive (ACTG 298)
Pollard RB, Tierney C, Havlir D, Tebas P, Fox L, Smeaton L, Richman D, Friedland GH. A Phase II Randomized Study of the Virologic and Immunologic Effect of Zidovudine + Stavudine versus Stavudine Alone and Zidovudine + Lamivudine in Patients with >300 CD4 Cells Who Were Antiretroviral Naive (ACTG 298). AIDS Research And Human Retroviruses 2002, 18: 699-704. PMID: 12167276, DOI: 10.1089/088922202760072311.Peer-Reviewed Original ResearchConceptsCD4 cell countStandard of careD4TViral loadWeek 12Copies/Cell countMedian baseline viral loadPhase II Randomized StudyD4T armDual nucleoside therapyAntiretroviral-naive patientsBaseline viral loadWeeks of monotherapyViral load reductionTreatment of patientsDevelopment of multidrugAntiretroviral-NaiveAntiviral suppressionNaive patientsCD4 cellsImmunologic effectsHIV infectionRandomized studyNucleoside therapy
2000
In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy
Havlir D, Tierney C, Friedland G, Pollard R, Smeaton L, Sommadossi J, Fox L, Kessler H, Fife K, Richman D. In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy. The Journal Of Infectious Diseases 2000, 182: 321-325. PMID: 10882616, DOI: 10.1086/315683.Peer-Reviewed Original ResearchConceptsCD4 cell countD4TCell countD4T armD4T monotherapyWeeks of therapyHuman immunodeficiency virusCopies/mLGreater antiviral activityT monotherapyHIV RNACurrent regimenImmunodeficiency virusPharmacologic antagonismCombination therapyMean reductionZidovudineAntiviral activityVivo antagonismProgressive declinePatientsCells/DdIIntracellular levelsTherapyInteraction of Methadone with Didanosine and Stavudine
Rainey P, Friedland G, McCanceKatz E, Andrews L, Mitchell S, Charles C, Jatlow P. Interaction of Methadone with Didanosine and Stavudine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 24: 241-248. PMID: 10969348, DOI: 10.1097/00126334-200007010-00007.Peer-Reviewed Original ResearchConceptsD4TMethadone therapyMore nucleoside analoguesStable methadone therapyActive antiretroviral therapyEffects of methadonePeak drug concentrationInjection drug usersInteraction of methadoneOpiate-dependent injection drug usersCurrent HAART regimensTime-concentration curveExtrapolated AUCMethadone dispositionAntiretroviral therapyHAART regimensDosing intervalTrough levelsMethadone treatmentHistorical controlsLarge dosesStudy subjectsDrug usersMethadoneDrug concentrationsInteraction of Methadone with Didanosine and Stavudine
Rainey P, Friedland G, McCance-Katz E, Andrews L, Mitchell S, Charles C, Jatlow P. Interaction of Methadone with Didanosine and Stavudine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 24: 241-248. DOI: 10.1097/00042560-200007010-00008.Peer-Reviewed Original ResearchConceptsD4TMethadone therapyMore nucleoside analoguesStable methadone therapyActive antiretroviral therapyEffects of methadonePeak drug concentrationInjection drug usersInteraction of methadoneOpiate-dependent injection drug usersCurrent HAART regimensTime-concentration curveExtrapolated AUCMethadone dispositionAntiretroviral therapyHAART regimensDosing intervalTrough levelsMethadone treatmentHistorical controlsLarge dosesStudy subjectsDrug usersMethadoneDrug concentrations
1999
Stavudine Resistance: An Update on Susceptibility following Prolonged Therapy
Lin P, González C, Griffith B, Friedland G, Calvez V, Ferchal F, Schinazi R, Shepp D, Ashraf A, Wainberg M, Soriano V, Mellors J, Colonno R. Stavudine Resistance: An Update on Susceptibility following Prolonged Therapy. Antiviral Therapy 1999, 4: 21-28. PMID: 10682125, DOI: 10.1177/135965359900400103.Peer-Reviewed Original ResearchConceptsPost-treatment isolatesStavudine resistanceStavudine therapyFirst-line combination therapyAmino acid changesUse of stavudineMonths of treatmentClinical HIV-1HIV-1 strainsNucleoside analoguesAcid changesProlonged therapyHIV patientsConsistent amino acid changesCombination therapyMulti-resistant phenotypeHIV-1Lower incidenceReverse transcriptase geneClinical isolatesTherapyDrug sensitivityPatientsTranscriptase geneCurrent report
1996
Effect of Stavudine on Human Immunodeficiency Virus Type 1 Virus Load as Measured by Quantitative Mononuclear Cell Culture, Plasma RNA, and Immune Complex-Dissociated Antigenemia
Griffith B, Brett-Smith H, Kim G, Mellors J, Chacko T, Garner R, Cheng Y, Alcabes P, Friedland G. Effect of Stavudine on Human Immunodeficiency Virus Type 1 Virus Load as Measured by Quantitative Mononuclear Cell Culture, Plasma RNA, and Immune Complex-Dissociated Antigenemia. The Journal Of Infectious Diseases 1996, 173: 1252-1255. PMID: 8627080, DOI: 10.1093/infdis/173.5.1252.Peer-Reviewed Original ResearchConceptsAntiviral effectHuman immunodeficiency virus type 1Peripheral blood mononuclear cellsImmunodeficiency virus type 1Effects of stavudineWeeks of therapyTime pointsBaseline median valuesBlood mononuclear cellsMononuclear cell culturesVirus type 1Antigen levelsMononuclear cellsPolymerase chain reactionVirus loadPlasma RNAWeek 4Baseline valuesImmune complexesStavudineVirus titersType 1Chain reactionPatientsTherapyStavudine (d4T, Zerit®)
Friedland G, Dunkle L, Cross A. Stavudine (d4T, Zerit®). Advances In Experimental Medicine And Biology 1996, 394: 271-277. PMID: 8815691, DOI: 10.1007/978-1-4757-9209-6_24.Peer-Reviewed Original ResearchConceptsAdvanced HIV-1 infectionEffects of stavudinePrior zidovudine therapyHIV-1 infectionImmunologic deteriorationAcceptable toxicityZidovudine therapyHIV diseaseClinical benefitSuch therapySurrogate markerClinical trialsDrug AdministrationStavudineTherapyBeneficial effectsU.S. FoodPatientsInfectionDiseaseAdministrationProgressionTrials